P PRIMESTOCKFINDER.COM

CUV Shares Clinuvel Pharmaceuticals Limited

ASX · ASX
$7.01 -1.54% Prices as of close 2026-10-26

Last in our picks 2026-10-26 — not in the current list; analysis below is from that screen

Established revenue base and potential vitiligo indication expansion provide defensive growth and catalyst optionality.

Future value: $17.36 (+147.62%) · 6-12 months · analyst consensus

Signal breakdown

  • ▸Phase III vitiligo data and FDA engagement could broaden SCENESSE market.
  • ▾Below 50-day MA (-16.3%)
  • ▾Near 52-week low (5.7% of range)
  • ▸~148% upside to price target

Is CUV a buy right now?

Trend: CUV is trading below the 50-day average (-15.64%), RSI 46 — neutral momentum, with a 3-month return of -24.54%.

Valuation & quality: Clinuvel Pharmaceuticals Limited trades on a trailing P/E of 10.6, forward P/E 10.0, PEG 0.65, price-to-book 1.30; fundamentals show net margin 36.1%, return on equity 13.2%, revenue growth -3.8% year on year.

Analyst consensus: 6 analysts have a mean 12-month price target of A$16.86 (+140.5% vs the last close; range A$7.00 – A$39.30), consensus rating “buy”.

Income: trailing dividend yield 0.70%.

Our screen: BUY (score 2) — Established revenue base and potential vitiligo indication expansion provide defensive growth and catalyst optionality.

Computed from end-of-day data; not personal advice.

12-month price chart

11.9 7.01 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-26 (AUD). Range 7.01 – 11.9.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-2.70%-6.40%+0.10%+12.60%-11.90%-11.50%+7.20%-18.50%

Fundamentals

Market cap
$353.9M
P/E (ttm)
10.6
Forward P/E
10.0
EPS (ttm)
$0.66
Price / book
1.30
PEG
0.65
Beta
0.58
Net margin
36.1%
ROE
13.2%
Revenue growth
-3.8%
Earnings growth
5.3%
Revenue (ttm)
$94.0M
Free cash flow
$25.4M
Debt / equity
1%
Dividend yield
0.70%
52-wk range
$6.62 – $13.48
Volume
214,170
Avg volume (3m)
147,778

Analyst price target

Mean target
$16.86
Low
$7.00
High
$39.30
Analysts
6
Consensus
BUY

Technical signals

RSI (14)
45.9
vs 50-day MA
-15.64%
1-mo return
-14.20%
3-mo return
-24.54%
Volume z-score
0.99

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.